thalidomide has been researched along with Ovarian Neoplasms in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 8.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 6.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 4.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies." | 2.79 | A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ( Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E, 2014) |
| "Lenalidomide is an anti-angiogenic IMiD(®) immunomodulatory drug." | 2.76 | A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. ( Carter, JS; Downs, LS, 2011) |
| "Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20)." | 2.76 | A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. ( Blann, AD; Braybrooke, JP; Ganesan, TS; Han, C; Jenkins, A; Kaur, K; Madhusudan, S; Muthuramalingam, SR; Perren, T; Wilner, S, 2011) |
| "Thalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic." | 2.75 | Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation ( Benbrook, DM; Brady, MF; Darcy, KM; Edmonds, P; Hurteau, JA; Ivanov, I; Mannel, RS; McGuire, WP; Pearl, ML; Tewari, KS; Zanotti, K, 2010) |
| " The majority of adverse events were grades 1-2, including fatigue (25/80 cycles), nausea/vomiting (23/80), constipation (13/80), abdominal pain (17/80), rash (12/80), neutropenia (12/80), and anemia (12/80)." | 2.73 | Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. ( Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM, 2007) |
| "Thalidomide is an antiangiogenic agent with immune modulating potential." | 2.73 | A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. ( Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA, 2008) |
| "Thalidomide is an anti-angiogenesis agent that has shown activity in some solid tumors." | 2.72 | Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. ( Chan, JK; Cheung, MK; Ciaravino, G; Husain, A; Manuel, MR; Teng, NN, 2006) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 2.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "Epithelial ovarian cancer (EOC) recurrence is common following treatment with cytoreductive surgery and adjuvant chemotherapy." | 1.35 | Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. ( Leath, CA; Phippen, NT, 2009) |
| "Thalidomide is an oral immunomodulatory agent with antiangiogenic properties and activity in ovarian cancer." | 1.35 | Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. ( Buttin, BM; Moore, MJ, 2008) |
| "Treatment with thalidomide is a potentially useful antitumor therapy for ovarian cancer." | 1.33 | [Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice]. ( Cao, ZY; Li, W; Peng, ZL, 2005) |
| "Thalidomide has been used to treat a variety of diseases ranging from alleviation of autoimmune disorders to prevention of metastasis of cancers." | 1.33 | Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. ( Haruta, S; Inagaki, K; Kanayama, N; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Kondo, T; Kurita, N; Sakamoto, Y; Terao, T; Yagyu, T; Yamada, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noblejas-López, MDM | 1 |
| Nieto-Jimenez, C | 1 |
| Burgos, M | 1 |
| Gómez-Juárez, M | 1 |
| Montero, JC | 1 |
| Esparís-Ogando, A | 1 |
| Pandiella, A | 1 |
| Galán-Moya, EM | 1 |
| Ocaña, A | 1 |
| Selle, F | 1 |
| Sevin, E | 1 |
| Ray-Coquard, I | 1 |
| Mari, V | 1 |
| Berton-Rigaud, D | 1 |
| Favier, L | 1 |
| Fabbro, M | 1 |
| Lesoin, A | 1 |
| Lortholary, A | 1 |
| Pujade-Lauraine, E | 1 |
| Phippen, NT | 1 |
| Leath, CA | 1 |
| Hurteau, JA | 1 |
| Brady, MF | 1 |
| Darcy, KM | 1 |
| McGuire, WP | 1 |
| Edmonds, P | 1 |
| Pearl, ML | 1 |
| Ivanov, I | 1 |
| Tewari, KS | 1 |
| Mannel, RS | 1 |
| Zanotti, K | 1 |
| Benbrook, DM | 1 |
| Carter, JS | 1 |
| Downs, LS | 2 |
| Muthuramalingam, SR | 1 |
| Braybrooke, JP | 1 |
| Blann, AD | 1 |
| Madhusudan, S | 1 |
| Wilner, S | 1 |
| Jenkins, A | 1 |
| Han, C | 1 |
| Kaur, K | 1 |
| Perren, T | 1 |
| Ganesan, TS | 1 |
| Gordinier, ME | 2 |
| Dizon, DS | 2 |
| Li, W | 1 |
| Peng, ZL | 1 |
| Cao, ZY | 1 |
| Kobayashi, H | 1 |
| Yagyu, T | 1 |
| Kondo, T | 1 |
| Kurita, N | 1 |
| Inagaki, K | 1 |
| Haruta, S | 1 |
| Kawaguchi, R | 1 |
| Kitanaka, T | 1 |
| Sakamoto, Y | 1 |
| Yamada, Y | 1 |
| Kanayama, N | 1 |
| Terao, T | 1 |
| Chan, JK | 2 |
| Manuel, MR | 1 |
| Ciaravino, G | 1 |
| Cheung, MK | 1 |
| Husain, A | 2 |
| Teng, NN | 2 |
| Zhang, MM | 1 |
| Guo, HY | 1 |
| Weitzen, S | 1 |
| Disilvestro, PA | 1 |
| Moore, RG | 1 |
| Granai, CO | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Judson, PL | 1 |
| Argenta, PA | 1 |
| Ghebre, R | 1 |
| Geller, MA | 1 |
| Bliss, RL | 1 |
| Boente, MP | 1 |
| Nahhas, WA | 1 |
| Abu-Ghazaleh, SZ | 1 |
| Chen, MD | 1 |
| Carson, LF | 1 |
| Buttin, BM | 1 |
| Moore, MJ | 1 |
| Braun, AG | 2 |
| Dailey, JP | 1 |
| Eisen, T | 1 |
| Boshoff, C | 1 |
| Mak, I | 1 |
| Sapunar, F | 1 |
| Vaughan, MM | 1 |
| Pyle, L | 1 |
| Johnston, SR | 1 |
| Ahern, R | 1 |
| Smith, IE | 1 |
| Gore, ME | 1 |
| Eisen, TG | 1 |
| Jeyakumar, A | 1 |
| Chalas, E | 1 |
| Hindenburg, A | 1 |
| Abramson, N | 1 |
| Stokes, PK | 1 |
| Luke, M | 1 |
| Marks, AR | 1 |
| Harris, JM | 1 |
| Weinreb, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Lipo[NCT01111903] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma[NCT00179712] | Phase 1/Phase 2 | 60 participants | Interventional | 2005-04-30 | Completed | ||
| A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer[NCT00004876] | Phase 2 | 30 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Ovarian Neoplasms
| Article | Year |
|---|---|
Dyspnea during thalidomide treatment for advanced ovarian cancer.
Topics: Adult; Aged; Dyspnea; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Lo | 2005 |
Thalidomide in solid tumors: the London experience.
Topics: Adult; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II a | 2000 |
9 trials available for thalidomide and Ovarian Neoplasms
| Article | Year |
|---|---|
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epit | 2014 |
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormo | 2010 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug- | 2011 |
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; California; Drug Administration Schedule | 2006 |
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, | 2007 |
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Midd | 2008 |
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Topics: Adult; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Lymphokines; Male; Me | 2000 |
Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Sero | 2002 |
10 other studies available for thalidomide and Ovarian Neoplasms
| Article | Year |
|---|---|
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Fem | 2019 |
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2009 |
[Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice].
Topics: Animals; Cell Proliferation; Cyclophosphamide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude | 2005 |
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chondrosarcoma; Drug Syne | 2005 |
Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Case-Control Studies; Di | 2007 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |
Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
Topics: Angiogenesis Inhibitors; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Recurren | 2008 |
Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces.
Topics: Animals; Cell Adhesion; Cells, Cultured; Concanavalin A; Female; Mice; Mice, Inbred C3H; Microsomes, | 1981 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Res | 2001 |
Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes.
Topics: Animals; Biotransformation; Cell Line; Drug Stability; Female; Hydrogen-Ion Concentration; Hydrolysi | 1985 |